$ACHV

Achieve Life (NASDAQ: ACHV) director keeps 208,249 shares after sale

Achieve Life (ACHV) director Richard Alistair Stewart sold 20,626 shares at an average price of $8.493, retaining 208,249 shares directly and 1,241 indirectly. The sale occurred on August 19, 2026, with prices ranging from $8.4536 to $8.52 per share.

Original reporting
Published Aug 21, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 3:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ACHV
Bearish
medium confidence
Mentioned
$ACHV
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ACHVBearishLow
01

Why it matters

The transaction provides fresh insider information for traders.

02

Market read

Insider sell of a micro‑cap can influence short‑term price action.

03

What to watch

Stewart's indirect holdings via his spouse and Ricanto Limited may offset perceived dilution.

Relevance 4/10Novelty 4/10Timing: post‑market August 19, 2026

Background

Form 4 filing disclosed a director's recent stock sale.

Company-level read

Ticker impact

$ACHVBearishMedium confidence
Context

Director Richard Alistair Stewart sold 20,626 shares at a weighted average $8.493, leaving 208,249 shares held.

Expected impact

Potential slight dip in share price as market digests the sell.

Evidence & confidence

A $175K sale by a director is a material signal for a micro‑cap, but the amount is relatively small.

Market effects

Minimal impact on the broader biotech sector.

Limited to U.S. over‑the‑counter trading of ACHV.

No global relevance beyond the stock itself.

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Richard Alistair Stewart

    ACHV director who sold 20,626 shares.

Related articles

$ACHVMed

Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

ACHIEVE LIFE SCIENCES, INC. (ACHV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following

$ACHVMedAI 8/10

Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Achieve Life Sciences (Nasdaq: ACHV) reported Q2 2026 results and updates on cytisinicline for nicotine dependence. The FDA issued a Complete Response Letter on June 20, 2026 citing cGMP and labeling issues, with no clinical efficacy or safety deficiencies. Achieve closed a private placement up to $354M and expects NDA resubmission in Q4 2026 and potential FDA approval in H1 2027. Cash was $187.3M at June 30, 2026.

$ACHVMed

Achieve closes $261.5M AAA HELOC securitization

Achieve announced it closed a $261.5M securitization of newly originated HELOCs, its first deal of 2026 and ninth overall. The pool covers 3,129 lines with about $261.5M unpaid principal and $276.5M total credit line as of June 30. S&P Global Ratings and Morningstar DBRS assigned ratings to six rated and three unrated note classes.

$GISMed

General Mills Announces Dana McNabb As CEO

General Mills' board elected Dana McNabb, current COO, as CEO effective January 2027, succeeding Jeff Harmening, who will become executive chair. McNabb, with 27 years at the company, has led key operating segments and functions. She aims to drive profitable growth through digital demand and supply chain modernization, building on Harmening's foundation.

$GISMed

General Mills Names First Woman CEO

General Mills has named Dana McNabb as its next CEO, the first woman to lead the company. McNabb, currently COO, will take over on January 1. Current CEO Jeff Harmening will become executive chairman. The board unanimously approved the change.